What is ACADIA Pharmaceuticals Inc.'s (ACAD) StockRank?

MoatMap's StockRank for ACADIA Pharmaceuticals Inc. (ACAD) is 62/100, with a Hold signal. This is a composite score combining Quality (71), Value (43), and Momentum (42) factor ranks across MoatMap's 20,000+ stock universe.

Does ACADIA Pharmaceuticals Inc. have an economic moat?

ACADIA Pharmaceuticals Inc. (ACAD) has a Quality factor score of 71/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is ACADIA Pharmaceuticals Inc. a buy, hold, or sell?

MoatMap's current signal for ACADIA Pharmaceuticals Inc. (ACAD) is Hold, based on a StockRank of 62/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is ACADIA Pharmaceuticals Inc. in?

ACADIA Pharmaceuticals Inc. (ACAD) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ACAD

HOLD

ACADIA Pharmaceuticals Inc. · Healthcare · United States · $4.3B · Avg Vol: $43M/d

StockRank

Get insider-trade alerts

P/E (TTM)

11.6x

ROE

37.3%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Its flagship product, NUPLAZID (pimavanserin), addresses Parkinson's disease psychosis, providing a proprietary solution in a high-unmet-need area. ACADIA operates as a niche player targeting specific neurological conditions with advanced drug candidates and patent protection.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	517.2M	726.4M	957.8M	1.1B	27.5%	1.1B	1.2B	1.4B	14.3%
EPS	-1.34	-0.37	1.37	2.32	69.3%	2.17	—	—	—
Shares	162.1M	164.7M	166.7M	170.3M	+5.1%	171.2M	—	—	—
Debt	62.0M	57.2M	52.0M	52.2M	-5.6%	50.8M	—	—	—
Equity	400.4M	431.8M	732.8M	1.2B	45.3%	—	—	—	—
Op CF	-114.0M	16.7M	157.7M	109.8M	156.4%	123.5M	—	—	—
Inv CF	73.2M	32.0M	-30.5M	-302.6M	—	—	—	—	—
Fin CF	8.2M	25.1M	6.8M	49.9M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+20.4%

SMA 50SMA 200

$25.39

RSI (14)

40.6

52W High

$28.35

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

8.1%68.3

ROE

37.3%95.4

GP/Assets

43.1%83.0

Op. Margin

-1.7%34.5

FCF/Assets

9.9%86.3

Piotroski

668.3

Int. Cover

—N/A

D/E Ratio

0.04x72.8

Current Ratio

3.59x60.4

Value

P/E (TTM)

11.6x85.3

EV/EBITDA

37.7x14.8

P/FCF

27.6x45.5

P/B

3.4x38.7

P/S

3.9x48.8

Div Yield

—N/A

Momentum

52W High %

90%85.8

RS 6M

-13%55.8

SMA 50/200

0.99x61.7

EPS Rev 4W

-4.3%9.3

EPS Rev 12W

-10.3%13.2

EPS Improve

-61%8.4

Q Growth

-81%3.1

FUNDAMENTALS

Market Cap

$4.3B

P/E (Forward)

29.4x

Gross Margin

61.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ACAD are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ACAD	ACADIA Pharmaceuticals Inc.(you)	$4.3B	62	HOLD
VCEL	Vericel Corporation	$2.3B	65	HOLD
0I3Q.L	Corcept Therapeutics Incorporated	$5.7B	73	BUY
TVTX	Travere Therapeutics, Inc.	$5.3B	48	HOLD
LGND	Ligand Pharmaceuticals Incorporated	$6.0B	74	BUY
ELVN	Enliven Therapeutics, Inc.	$3.8B	44	HOLD
FTRE	Fortrea Holdings Inc.	$1.8B	58	HOLD
MIRM	Mirum Pharmaceuticals, Inc.	$6.9B	47	HOLD
TECH	Bio-Techne Corporation	$11.2B	67	BUY
PTCT	PTC Therapeutics, Inc.	$6.4B	45	HOLD

Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%

Price	$25.39
Market Cap	$4.3B
P/E (TTM)	11.56
P/E (Forward)	29.36
Price/Book	3.44
Return on Equity	37.3%
Return on Invested Capital	8.1%
Debt/Equity	0.04x
Gross Margin	61.6%
Operating Margin	-1.7%
Revenue Growth	9.7%
Free Cash Flow	$154M